Skip CCR Main Navigation National Cancer Institute National Cancer Institute U.S. National Institutes of Health
CCR - For Our Staff| Home |

Our Science – Waldmann Website

Thomas A. Waldmann, M.D.

Selected Publications

1)  Uchiyama T, Broder S, Waldmann TA.
A monoclonal antibody (anti-Tac) reactive with activated and functionally mature human T cells. I. Production of anti-Tac monoclonal antibody and distribution of Tac (+) cells.
J. Immunol. 126: 1393-7, 1981.
2)  Burton JD, Bamford RN, Peters C, Grant AJ, Kurys G, Goldman CK, Brennan J, Roessler E, Waldmann TA.
A lymphokine, provisionally designated interleukin T and produced by a human adult T-cell leukemia line, stimulates T-cell proliferation and the induction of lymphokine-activated killer cells.
Proc. Natl. Acad. Sci. U.S.A. 91: 4935-9, 1994.
3)  Waldmann TA.
The biology of interleukin-2 and interleukin-15: implications for cancer therapy and vaccine design.
Nat. Rev. Immunol. 6: 595-601, 2006.
4)  Waldmann TA, Lugli E, Roederer M, Perera LP, Smedley JV, Macallister RP, Goldman CK, Bryant BR, Decker JM, Fleisher TA, Lane HC, Sneller MC, Kurlander RJ, Kleiner DE, Pletcher JM, Figg WD, Yovandich JL, Creekmore SP.
Safety (toxicity), pharmacokinetics, immunogenicity, and impact on elements of the normal immune system of recombinant human IL-15 in rhesus macaques.
Blood. 117: 4787-95, 2011.
5)  Ju W, Zhang M, Jiang JK, Thomas CJ, Oh U, Bryant BR, Chen J, Sato N, Tagaya Y, Morris JC, Janik JE, Jacobson S, Waldmann TA.
CP-690,550, a therapeutic agent, inhibits cytokine-mediated Jak3 activation and proliferation of T cells from patients with ATL and HAM/TSP.
Blood. 117: 1938-46, 2011.
6)  Nguyen VP, Chen J, Petrus MN, Goldman CK, Kruhlak MJ, Bamford RN, Waldmann TA.
A New Domain in the Toll/IL-1R Domain-Containing Adaptor Inducing Interferon-ß Factor Protein Amino Terminus Is Important for Tumor Necrosis Factor-a Receptor-Associated Factor 3 Association, Protein Stabilization and Interferon Signaling.
J Innate Immun. 6: 377-93, 2014.
7)  Ju W, Zhang M, Petrus M, Maeda M, Pise-Masison CA, Waldmann TA.
Combination of 9-aminoacridine with Campath-1H provides effective therapy for a murine model of adult T-cell leukemia.
Retrovirology. 11: 43, 2014.
8)  Valkenburg SA, Li OT, Mak PW, Mok CK, Nicholls JM, Guan Y, Waldmann TA, Peiris JS, Perera LP, Poon LL.
IL-15 adjuvanted multivalent vaccinia-based universal influenza vaccine requires CD4+ T cells for heterosubtypic protection.
Proc. Natl. Acad. Sci. U.S.A. 111: 5676-81, 2014.
9)  Morris JC, Ramlogan-Steel CA, Yu P, Black BA, Mannan P, Allison JP, Waldmann TA, Steel JC.
Vaccination with tumor cells expressing IL-15 and IL-15Ra inhibits murine breast and prostate cancer.
Gene Ther. 21: 393-401, 2014.
10)  Bellon M, Ko NL, Lee MJ, Yao Y, Waldmann TA, Trepel JB, Nicot C.
Adult T-cell leukemia cells overexpress Wnt5a and promote osteoclast differentiation.
Blood. 121: 5045-54, 2013.
11)  Shah NN, Waldmann TA.
GVL for ATL?.
Blood. 121: 6-7, 2013.
12)  Chen J, Feigenbaum L, Awasthi P, Butcher DO, Anver MR, Golubeva YG, Bamford R, Zhang X, St Claire MB, Thomas CJ, Discepolo V, Jabri B, Waldmann TA.
Insulin-dependent diabetes induced by pancreatic beta cell expression of IL-15 and IL-15Ra.
Proc. Natl. Acad. Sci. U.S.A. 110: 13534-9, 2013.
13)  Chen J, Pise-Masison CA, Shih JH, Morris JC, Janik JE, Conlon KC, Keating A, Waldmann TA.
Markedly additive antitumor activity with the combination of a selective survivin suppressant YM155 and alemtuzumab in adult T-cell leukemia.
Blood. 121: 2029-37, 2013.
14)  Waldmann TA, Conlon KC, Stewart DM, Worthy TA, Janik JE, Fleisher TA, Albert PS, Figg WD, Spencer SD, Raffeld M, Decker JR, Goldman CK, Bryant BR, Petrus MN, Creekmore SP, Morris JC.
Phase 1 trial of IL-15 trans presentation blockade using humanized Mik-Beta-1 mAb in patients with T-cell large granular lymphocytic leukemia.
Blood. 121: 476-84, 2013.
15)  Merkel TJ, Perera PY, Lee GM, Verma A, Hiroi T, Yokote H, Waldmann TA, Perera LP.
Protective-antigen (PA) based anthrax vaccines confer protection against inhalation anthrax by precluding the establishment of a systemic infection.
Hum Vaccin Immunother. 9: 1841-8, 2013.
16)  Lugli E, Dominguez MH, Gattinoni L, Chattopadhyay PK, Bolton DL, Song K, Klatt NR, Brenchley JM, Vaccari M, Gostick E, Price DA, Waldmann TA, Restifo NP, Franchini G, Roederer M.
Superior T memory stem cell persistence supports long-lived T cell memory.
J. Clin. Invest. 123: 594-9, 2013.
17)  Waldmann TA.
The biology of IL-15: implications for cancer therapy and the treatment of autoimmune disorders.
J. Investig. Dermatol. Symp. Proc. 16: S28-30, 2013.
18)  Yokoyama S, Perera PY, Waldmann TA, Hiroi T, Perera LP.
Tofacitinib, a janus kinase inhibitor demonstrates efficacy in an IL-15 transgenic mouse model that recapitulates pathologic manifestations of celiac disease.
J. Clin. Immunol. 33: 586-94, 2013.
19)  Zhang M, Ju W, Yao Z, Yu P, Wei B, Simpson RM, Waitz R, Fassò M, Allison JP, Waldmann TA.
Augmented IL-15Ralpha Expression by CD40 Activation Is Critical in Synergistic CD8 T Cell-Mediated Antitumor Activity of Anti-CD40 Antibody with IL-15 in TRAMP-C2 Tumors in Mice.
J Immunol. 188: 6156-64, 2012.
20)  Schmitz R, Young RM, Ceribelli M, Jhavar S, Xiao W, Zhang M, Wright G, Shaffer AL, Hodson DJ, Buras E, Liu X, Powell J, Yang Y, Xu W, Zhao H, Kohlhammer H, Rosenwald A, Kluin P, Müller-Hermelink HK, Ott G, Gascoyne RD, Connors JM, Rimsza LM, Campo E, Jaffe ES, Delabie J, Smeland EB, Ogwang MD, Reynolds SJ, Fisher RI, Braziel RM, Tubbs RR, Cook JR, Weisenburger DD, Chan WC, Pittaluga S, Wilson W, Waldmann TA, Rowe M, Mbulaiteye SM, Rickinson AB, Staudt LM.
Burkitt lymphoma pathogenesis and therapeutic targets from structural and functional genomics.
Nature. 490: 116-20, 2012.
21)  Yang Y, Shaffer AL, Emre NC, Ceribelli M, Zhang M, Wright G, Xiao W, Powell J, Platig J, Kohlhammer H, Young RM, Zhao H, Yang Y, Xu W, Buggy JJ, Balasubramanian S, Mathews LA, Shinn P, Guha R, Ferrer M, Thomas C, Waldmann TA, Staudt LM.
Exploiting synthetic lethality for the therapy of ABC diffuse large B cell lymphoma.
Cancer Cell. 21: 723-37, 2012.
22)  Chen J, Petrus M, Bamford R, Shih JH, Morris JC, Janik JE, Waldmann TA.
Increased serum soluble IL-15Ralpha levels in T-cell large granular lymphocyte leukemia.
Blood. 119: 137-43, 2012.
23)  Steel JC, Waldmann TA, Morris JC.
Interleukin-15 biology and its therapeutic implications in cancer.
Trends Pharmacol. Sci. 33: 35-41, 2012.
24)  Müller JR, Waldmann TA, Kruhlak MJ, Dubois S.
Paracrine and transpresentation functions of IL-15 are mediated by diverse splice versions of IL-15Ralpha in human monocytes and dendritic cells.
J. Biol. Chem. 287: 40328-38, 2012.
25)  Simone CB, Morris JC, Stewart DM, Urquhart NE, Janik JE, Kreitman RJ, Lita E, Conlon K, Wharfe G, Waldmann TA, Kaushal A.
Radiation therapy for the management of patients with HTLV-1-associated adult T-cell leukemia/lymphoma.
Blood. 120: 1816-9, 2012.
26)  Müller JR, Waldmann TA, Dubois S.
Selective dependence of H2-M3-restricted CD8 responses on IL-15.
J. Immunol. 188: 2575-82, 2012.
27)  Yu P, Steel JC, Zhang M, Morris JC, Waitz R, Fasso M, Allison JP, Waldmann TA.
Simultaneous inhibition of two regulatory T-cell subsets enhanced Interleukin-15 efficacy in a prostate tumor model.
Proc. Natl. Acad. Sci. U.S.A. 109: 6187-92, 2012.
28)  Perera PY, Lichy JH, Waldmann TA, Perera LP.
The role of interleukin-15 in inflammation and immune responses to infection: implications for its therapeutic use.
Microbes Infect. 14: 247-61, 2012.
29)  Wuest SC, Edwan JH, Martin JF, Han S, Perry JS, Cartagena CM, Matsuura E, Maric D, Waldmann TA, Bielekova B.
A role for interleukin-2 trans-presentation in dendritic cell-mediated T cell activation in humans, as revealed by daclizumab therapy.
Nat. Med. 17: 604-9, 2011.
30)  Vyas VV, Esposito D, Sumpter TL, Broadt TL, Hartley J, Knapp GC, Cheng W, Jiang MS, Roach JM, Yang X, Giardina SL, Mitra G, Yovandich JL, Creekmore SP, Waldmann TA, Zhu J.
Clinical manufacturing of recombinant human interleukin 15. I. Production cell line development and protein expression in E. coli with stop codon optimization.
Biotechnol. Prog. 28: 497-507, 2011.
31)  DePaolo RW, Abadie V, Tang F, Fehlner-Peach H, Hall JA, Wang W, Marietta EV, Kasarda DD, Waldmann TA, Murray JA, Semrad C, Kupfer SS, Belkaid Y, Guandalini S, Jabri B.
Co-adjuvant effects of retinoic acid and IL-15 induce inflammatory immunity to dietary antigens.
Nature. 471: 220-4, 2011.
32)  Sato N, Sabzevari H, Fu S, Ju W, Petrus MN, Bamford RN, Waldmann TA, Tagaya Y.
Development of an IL-15-autocrine CD8 T-cell leukemia in IL-15-transgenic mice requires the cis expression of IL-15Ralpha.
Blood. 117: 4032-40, 2011.
33)  Elliott NE, Cleveland SM, Grann V, Janik J, Waldmann TA, Davé UP.
FERM domain mutations induce gain of function in JAK3 in adult T-cell leukemia/lymphoma.
Blood. 118: 3911-21, 2011.
34)  Sneller MC, Kopp WC, Engelke KJ, Yovandich JL, Creekmore SP, Waldmann TA, Lane HC.
IL-15 administered by continuous infusion to rhesus macaques induces massive expansion of CD8+ T effector memory population in peripheral blood.
Blood. 118: 6845-8, 2011.
35)  Steel J, Waldmann T, John M.
Interleukin-15 biology and its therapeutic implications in cancer.
Trends in Pharmacological Sciences. 33 (1): 35-41, 2011.
36)  Bielekova B, Richert N, Herman ML, Ohayon J, Waldmann TA, McFarland H, Martin R, Blevins G.
Intrathecal effects of daclizumab treatment of multiple sclerosis.
Neurology. 77: 1877-86, 2011.
37)  Chen J, Petrus M, Bryant BR, Nguyen VP, Goldman CK, Bamford R, Morris JC, Janik JE, Waldmann TA.
Autocrine/paracrine cytokine stimulation of leukemic cell proliferation in smoldering and chronic adult T-cell leukemia.
Blood. 116: 5948-56, 2010.
38)  Merkel TJ, Perera PY, Kelly VK, Verma A, Llewellyn ZN, Waldmann TA, Mosca JD, Perera LP.
Development of a highly efficacious vaccinia-based dual vaccine against smallpox and anthrax, two important bioterror entities.
Proc. Natl. Acad. Sci. U.S.A. 107: 18091-6, 2010.
39)  Kolibab K, Yang A, Derrick SC, Waldmann TA, Perera LP, Morris SL.
Highly persistent and effective prime/boost regimens against tuberculosis that use a multivalent modified vaccine virus Ankara-based tuberculosis vaccine with interleukin-15 as a molecular adjuvant.
Clin. Vaccine Immunol. 17: 793-801, 2010.
40)  Steel JC, Ramlogan CA, Yu P, Sakai Y, Forni G, Waldmann TA, Morris JC.
Interleukin-15 and its receptor augment dendritic cell vaccination against the neu oncogene through the induction of antibodies partially independent of CD4 help.
Cancer Res. 70: 1072-81, 2010.
41)  Pancewicz J, Taylor JM, Datta A, Baydoun HH, Waldmann TA, Hermine O, Nicot C.
Notch signaling contributes to proliferation and tumor formation of human T-cell leukemia virus type 1-associated adult T-cell leukemia.
Proc. Natl. Acad. Sci. U.S.A. 107: 16619-24, 2010.
42)  Yu P, Steel JC, Zhang M, Morris JC, Waldmann TA.
Simultaneous blockade of multiple immune system inhibitory checkpoints enhances antitumor activity mediated by interleukin-15 in a murine metastatic colon carcinoma model.
Clin. Cancer Res. 16: 6019-28, 2010.
43)  Zielinski RJ, Smedley JV, Perera PY, Silvera PM, Waldmann TA, Capala J, Perera LP.
Smallpox vaccine with integrated IL-15 demonstrates enhanced in vivo viral clearance in immunodeficient mice and confers long term protection against a lethal monkeypox challenge in cynomolgus monkeys.
Vaccine. 28: 7081-91, 2010.
44)  Lugli E, Goldman CK, Perera LP, Smedley J, Pung R, Yovandich JL, Creekmore SP, Waldmann TA, Roederer M.
Transient and persistent effects of IL-15 on lymphocyte homeostasis in nonhuman primates.
Blood. 116: 3238-48, 2010.
45)  Perera PY, Derrick SC, Kolibab K, Momoi F, Yamamoto M, Morris SL, Waldmann TA, Perera LP.
A multi-valent vaccinia virus-based tuberculosis vaccine molecularly adjuvanted with interleukin-15 induces robust immune responses in mice.
Vaccine. 27: 2121-7, 2009.
46)  Morris JC, Waldmann TA.
Antibody-based therapy of leukaemia.
Expert Rev Mol Med. 11: e29, 2009.
47)  Yokoyama S, Watanabe N, Sato N, Perera PY, Filkoski L, Tanaka T, Miyasaka M, Waldmann TA, Hiroi T, Perera LP.
Antibody-mediated blockade of IL-15 reverses the autoimmune intestinal damage in transgenic mice that overexpress IL-15 in enterocytes.
Proc. Natl. Acad. Sci. U.S.A. 106: 15849-54, 2009.
48)  O'Mahony D, Morris JC, Stetler-Stevenson M, Matthews H, Brown MR, Fleisher T, Pittaluga S, Raffeld M, Albert PS, Reitsma D, Kaucic K, Hammershaimb L, Waldmann TA, Janik JE.
EBV-related lymphoproliferative disease complicating therapy with the anti-CD2 monoclonal antibody, siplizumab, in patients with T-cell malignancies.
Clin. Cancer Res. 15: 2514-22, 2009.
49)  Bielekova B, Howard T, Packer AN, Richert N, Blevins G, Ohayon J, Waldmann TA, McFarland HF, Martin R.
Effect of anti-CD25 antibody daclizumab in the inhibition of inflammation and stabilization of disease progression in multiple sclerosis.
Arch. Neurol. 66: 483-9, 2009.
50)  Chen J, Zhang M, Ju W, Waldmann TA.
Effective treatment of a murine model of adult T-cell leukemia using depsipeptide and its combination with unmodified daclizumab directed toward CD25.
Blood. 113: 1287-93, 2009.
51)  Pise-Masison CA, Radonovich M, Dohoney K, Morris JC, O'Mahony D, Lee MJ, Trepel J, Waldmann TA, Janik JE, Brady JN.
Gene expression profiling of ATL patients: compilation of disease-related genes and evidence for TCF4 involvement in BIRC5 gene expression and cell viability.
Blood. 113: 4016-26, 2009.
52)  Zhang M, Yao Z, Dubois S, Ju W, Müller JR, Waldmann TA.
Interleukin-15 combined with an anti-CD40 antibody provides enhanced therapeutic efficacy for murine models of colon cancer.
Proc. Natl. Acad. Sci. U.S.A. 106: 7513-8, 2009.
53)  Soman G, Yang X, Jiang H, Giardina S, Vyas V, Mitra G, Yovandich J, Creekmore SP, Waldmann TA, Quiñones O, Alvord WG.
MTS dye based colorimetric CTLL-2 cell proliferation assay for product release and stability monitoring of interleukin-15: assay qualification, standardization and statistical analysis.
J. Immunol. Methods. 348: 83-94, 2009.
54)  Kraynyak KA, Kutzler MA, Cisper NJ, Laddy DJ, Morrow MP, Waldmann TA, Weiner DB.
Plasmid-encoded interleukin-15 receptor alpha enhances specific immune responses induced by a DNA vaccine in vivo.
Hum. Gene Ther. 20: 1143-56, 2009.
55)  Zhang M, Yao Z, Garmestani K, Yu S, Goldman CK, Paik CH, Brechbiel MW, Carrasquillo JA, Waldmann TA.
Preclinical evaluation of an anti-CD25 monoclonal antibody, 7G7/B6, armed with the beta-emitter, yttrium-90, as a radioimmunotherapeutic agent for treating lymphoma.
Cancer Biother. Radiopharm. 24: 303-9, 2009.
56)  Poon LL, Leung YH, Nicholls JM, Perera PY, Lichy JH, Yamamoto M, Waldmann TA, Peiris JS, Perera LP.
Vaccinia virus-based multivalent H5N1 avian influenza vaccines adjuvanted with IL-15 confer sterile cross-clade protection in mice.
J. Immunol. 182: 3063-71, 2009.
57)  Bodnar A, Nizsaloczki E, Mocsar G, Szaloki N, Waldmann TA, Damjanovich S, Vamosi G.
A biophysical approach to IL-2 and IL-15 receptor function: localization, conformation and interactions.
Immunol. Lett. 116: 117-25, 2008.
58)  O'Mahony D, Debnath I, Janik J, Aisner D, Jaffe E, Waldmann T, Morris J.
Cardiac involvement with human T-cell lymphotrophic virus type-1-associated adult T-cell leukemia/lymphoma: The NIH experience.
Leuk. Lymphoma. 49: 439-46, 2008.
59)  Robinson MK, Shaller C, Garmestani K, Plascjak PS, Hodge KM, Yuan QA, Marks JD, Waldmann TA, Brechbiel MW, Adams GP.
Effective treatment of established human breast tumor xenografts in immunodeficient mice with a single dose of the alpha-emitting radioisotope astatine-211 conjugated to anti-HER2/neu diabodies.
Clin. Cancer Res. 14: 875-82, 2008.
60)  Yeh S, Wroblewski K, Buggage R, Li Z, Kurup SK, Sen HN, Dahr S, Sran P, Reed GF, Robinson R, Ragheb JA, Waldmann TA, Nussenblatt RB.
High-dose humanized anti-IL-2 receptor alpha antibody (daclizumab) for the treatment of active, non-infectious uveitis.
J. Autoimmun. 31: 91-7, 2008.
61)  Oh S, Perera LP, Terabe M, Ni L, Waldmann TA, Berzofsky JA.
IL-15 as a mediator of CD4+ help for CD8+ T cell longevity and avoidance of TRAIL-mediated apoptosis.
Proc. Natl. Acad. Sci. U.S.A. 105: 5201-6, 2008.
62)  Terabe M, Tagaya Y, Zhu Q, Granger L, Roederer M, Waldmann TA, Berzofsky JA.
IL-15 expands unconventional CD8alphaalphaNK1.1+ T cells but not Valpha14Jalpha18+ NKT cells.
J. Immunol. 180: 7276-86, 2008.
63)  Miyagawa F, Tagaya Y, Kim BS, Patel HJ, Ishida K, Ohteki T, Waldmann TA, Katz SI.
IL-15 serves as a costimulator in determining the activity of autoreactive CD8 T cells in an experimental mouse model of graft-versus-host-like disease.
J. Immunol. 181: 1109-19, 2008.
64)  Chen J, Petrus M, Bryant BR, Phuc Nguyen V, Stamer M, Goldman CK, Bamford R, Morris JC, Janik JE, Waldmann TA.
Induction of the IL-9 gene by HTLV-I Tax stimulates the spontaneous proliferation of primary adult T-cell leukemia cells by a paracrine mechanism.
Blood. 111: 5163-72, 2008.
65)  de Bakker B, Bodnar A, van Dijk EM, Vamosi G, Damjanovich S, Waldmann TA, van Hulst NF, Jenei A, Garcia-Parajo M.
Nanometer-scale organization of the alpha subunits of the receptors for IL2 and IL15 in human T lymphoma cells.
J. Cell. Sci. 121: 627-33, 2008.
66)  Dubois S, Patel HJ, Zhang M, Waldmann TA, Muller J.
Preassociation of IL-15 with IL-15R alpha-IgG1-Fc enhances its activity on proliferation of NK and CD8+/CD44high T cells and its antitumor action.
J. Immunol. 180: 2099-106, 2008.
67)  Morris JC, Waldmann TA, Janik JE.
Receptor-directed therapy of T-cell leukemias and lymphomas.
J Immunotoxicol. 5: 235-48, 2008.
68)  Buggage RR, Levy-Clarke G, Sen HN, Ursea R, Srivastava SK, Suhler EB, Altemare C, Velez G, Ragheb J, Chan C, Nussenblatt RB, Bamji AT, Sran P, Waldmann T, Thompson DJ.
A double-masked, randomized study to investigate the safety and efficacy of daclizumab to treat the ocular complications related to Behcet's disease.
Ocul. Immunol. Inflamm. 15: 63-70, 2007.
69)  O'Mahony D, Morris JC, Quinn C, Gao W, Wilson WH, Gause B, Pittaluga S, Neelapu S, Brown M, Fleisher TA, Gulley JL, Schlom J, Nussenblatt R, Albert P, Davis TA, Lowy I, Petrus M, Waldmann TA, Janik JE.
A pilot study of CTLA-4 blockade after cancer vaccine failure in patients with advanced malignancy.
Clin. Cancer Res. 13: 958-64, 2007.
70)  Waldmann TA.
Anti-Tac (daclizumab, Zenapax) in the treatment of leukemia, autoimmune diseases, and in the prevention of allograft rejection: a 25-year personal odyssey.
J. Clin. Immunol. 27: 1-18, 2007.
71)  Bene L, Kanyari Z, Bodnar A, Kappelmayer J, Waldmann TA, Vamosi G, Damjanovich L.
Colorectal carcinoma rearranges cell surface protein topology and density in CD4(+) T cells.
Biochem. Biophys. Res. Commun. 361: 202-7, 2007.
72)  Waldmann TA.
Daclizumab (anti-Tac, Zenapax) in the treatment of leukemia/lymphoma.
Oncogene. 26: 3699-703, 2007.
73)  Perera LP, Waldmann TA, Mosca JD, Baldwin N, Berzofsky JA, Oh SK.
Development of smallpox vaccine candidates with integrated interleukin-15 that demonstrate superior immunogenicity, efficacy, and safety in mice.
J. Virol. 81: 8774-83, 2007.
74)  Zhang M, Yao Z, Patel H, Garmestani K, Zhang Z, Talanov VS, Plascjak PS, Goldman CK, Janik JE, Brechbiel MW, Waldmann TA.
Effective therapy of murine models of human leukemia and lymphoma with radiolabeled anti-CD30 antibody, HeFi-1.
Proc. Natl. Acad. Sci. U.S.A. 104: 8444-8, 2007.
75)  Boyer JD, Robinson TM, Kutzler MA, Vansant G, Hokey DA, Kumar S, Parkinson R, Wu L, Sidhu MK, Pavlakis GN, Felber BK, Brown C, Silvera P, Lewis MG, Monforte J, Waldmann TA, Eldridge J, Weiner DB.
Protection against simian/human immunodeficiency virus (SHIV) 89.6P in macaques after coimmunization with SHIV antigen and IL-15 plasmid.
Proc. Natl. Acad. Sci. U.S.A. 104: 18648-53, 2007.
76)  Sato N, Patel HJ, Waldmann TA, Tagaya Y.
The IL-15/IL-15Ralpha on cell surfaces enables sustained IL-15 activity and contributes to the long survival of CD8 memory T cells.
Proc. Natl. Acad. Sci. U.S.A. 104: 588-93, 2007.
77)  Koon HB, Severy P, Hagg DS, Butler K, Hill T, Jones AG, Waldmann TA, Junghans RP.
Antileukemic effect of daclizumab in CD25 high-expressing leukemias and impact of tumor burden on antibody dosing.
Leuk. Res. 30: 190-203, 2006.
78)  Waldmann TA, Morris JC.
Development of antibodies and chimeric molecules for cancer immunotherapy.
Adv. Immunol. 90: 83-131, 2006.
79)  Waldmann TA.
Effective cancer therapy through immunomodulation.
Annu. Rev. Med. 57: 65-81, 2006.
80)  Zhang M, Yao Z, Zhang Z, Garmestani K, Goldman CK, Ravetch JV, Janik J, Brechbiel MW, Waldmann TA.
Effective therapy for a murine model of human anaplastic large-cell lymphoma with the anti-CD30 monoclonal antibody, HeFi-1, does not require activating Fc receptors.
Blood. 108: 705-10, 2006.
81)  Zhang Z, Zhang M, Garmestani K, Talanov VS, Plascjak PS, Beck B, Goldman C, Brechbiel MW, Waldmann TA.
Effective treatment of a murine model of adult T-cell leukemia using 211At-7G7/B6 and its combination with unmodified anti-Tac (daclizumab) directed toward CD25.
Blood. 108: 1007-12, 2006.
82)  Wani MA, Haynes LD, Kim J, Bronson CL, Chaudhury C, Mohanty S, Waldmann TA, Robinson JM, Anderson CL.
Familial hypercatabolic hypoproteinemia caused by deficiency of the neonatal Fc receptor, FcRn, due to a mutant beta2-microglobulin gene.
Proc. Natl. Acad. Sci. U.S.A. 103: 5084-9, 2006.
83)  Dubois S, Waldmann TA, Müller JR.
ITK and IL-15 support two distinct subsets of CD8+ T cells.
Proc. Natl. Acad. Sci. U.S.A. 103: 12075-80, 2006.
84)  Datta A, Bellon M, Sinha-Datta U, Bazarbachi A, Lepelletier Y, Canioni D, Waldmann TA, Hermine O, Nicot C.
Persistent inhibition of telomerase reprograms adult T-cell leukemia to p53-dependent senescence.
Blood. 108: 1021-9, 2006.
85)  Morris JC, Janik JE, White JD, Fleisher TA, Brown M, Tsudo M, Goldman CK, Bryant B, Petrus M, Top L, Lee CC, Gao W, Waldmann TA.
Preclinical and phase I clinical trial of blockade of IL-15 using Mikbeta1 monoclonal antibody in T cell large granular lymphocyte leukemia.
Proc. Natl. Acad. Sci. U.S.A. 103: 401-6, 2006.
86)  Talanov VS, Garmestani K, Regino CA, Milenic DE, Plascjak PS, Waldmann TA, Brechbiel MW.
Preparation and in vivo evaluation of a novel stabilized linker for 211At labeling of protein.
Nucl. Med. Biol. 33: 469-80, 2006.
87)  Bielekova B, Catalfamo M, Reichert-Scrivner S, Packer A, Cerna M, Waldmann TA, McFarland H, Henkart PA, Martin R.
Regulatory CD56(bright) natural killer cells mediate immunomodulatory effects of IL-2Ralpha-targeted therapy (daclizumab) in multiple sclerosis.
Proc. Natl. Acad. Sci. U.S.A. 103: 5941-6, 2006.
88)  Zhang M, Yao Z, Zhang Z, Garmestani K, Talanov VS, Plascjak PS, Yu S, Kim HS, Goldman CK, Paik CH, Brechbiel MW, Carrasquillo JA, Waldmann TA.
The Anti-CD25 Monoclonal Antibody 7G7/B6, Armed with the {alpha}-Emitter 211At, Provides Effective Radioimmunotherapy for a Murine Model of Leukemia.
Cancer Res. 66: 8227-32, 2006.
89)  Klebanoff C, Gattinoni L, Torabi-Parizi P, Kerstann K, Cardones A, Finkelstein S, Palmer D, Antony P, Hwang S, Rosenberg S, Waldmann T, Restifo N.
Central memory self/tumor-reactive CD8(+) T cells confer superior anti-tumor immunity compared with effector memory T cells.
Proc. Natl. Acad. Sci. USA. 102: 9571-76, 2005.
90)  Kutzler MA, Robinson TM, Chattergoon MA, Choo DK, Choo AY, Choe PY, Ramanathan MP, Parkinson R, Kudchodkar S, Tamura Y, Sidhu M, Roopchand V, Kim JJ, Pavlakis GN, Felber BK, Waldmann TA, Boyer JD, Weiner DB.
Coimmunization with an optimized IL-15 plasmid results in enhanced function and longevity of CD8 T cells that are partially independent of CD4 T cell help.
J. Immunol. 175(1): 112-23, 2005.
91)  Zhang M, Zhang Z, Goldman CK, Janik J, Waldmann TA.
Combination therapy for adult T-cell leukemia-xenografted mice: flavopiridol and anti-CD25 monoclonal antibody.
Blood. 105(3): 1231-6, 2005.
92)  Rubovsky B, Hajdu P, Krasznai Z, Gaspar Jr R, Waldmann T, Damjanovich S, Bene L.
Detection of channel proximity by nanoparticle-assisted delaying of toxin binding; a combined patch-clamp and flow cytometric transfer study.
Eur. Biophys J. 34(2): 127-43, 2005.
93)  Kobayashi H, Kawamoto S, Brechbiel MW, Bernardo M, Sato N, Waldmann TA, Tagaya Y, Choyke PL.
Detection of lymph node involvement in hematologic malignancies using micromagnetic resonance lymphangiography with a gadolinum-labeled dendrimer nanoparticle.
Neoplasia. 7: 984-91, 2005.
94)  Bene L, Szöllosi J, Szentesi G, Damjanovich L, Gáspár R, Waldmann TA, Damjanovich S.
Detection of receptor trimers on the cell surface by flow cytometric fluorescence energy homotransfer measurements.
Biochim Biophys Acta. 1744(2): 176-98, 2005.
95)  Kobayashi H, Dubois S, Sato N, Sabzevari H, Sakai Y, Waldmann TA, Tagaya Y.
Role of trans-cellular IL-15 presentation in the activation of NK cell-mediated killing, which leads to enhanced tumor immunosurveillance.
Blood. 105(2): 721-7, 2005.
96)  Dubois SP, Waldmann TA, Müller JR.
Survival adjustment of mature dendritic cells by IL-15.
Proc. Natl. Acad. Sci. U.S.A. 102: 8662-7, 2005.
97)  Waldmann TA.
Targeting the interleukin-15 system in rheumatoid arthritis.
Arthritis Rheum. 52: 2585-8, 2005.
98)  Zhang M, Zhang Z, Garmestani K, Goldman CK, Ravetch JV, Brechbiel MW, Carrasquillo JA, Waldmann TA.
Activating receptors are required for antitumor efficacy of the antibodies directed toward CD25 in a murine model of adult T-cell leukemia.
Cancer Res. 64 (16): 5825-5829, 2004.
99)  Kobayashi H, Reijnders K, English S, Yordanov AT, Milenic DE, Sowers AL, Citrin D, Krishna MC, Waldmann TA, Mitchell JB, Brechbiel MW.
Application of a macromolecular contrast agent for detection of alterations of tumor vessel permeability induced by radiation.
Clin. Cancer Res. 10(22): 7712-20, 2004.
100)  Janik JE, Morris JC, Pittaluga S, McDonald K, Raffeld M, Jaffe ES, Grant N, Gutierrez M, Waldmann TA, Wilson WH.
Elevated serum soluble interleukin-2 receptor levels in patients with anaplastic large cell lymphoma.
Blood. 104(10): 3355-7, 2004.
101)  Mandler R, Kobayashi H, Hinson ER, Brechbiel MW, Waldmann TA.
Herceptin-geldanamycin immunoconjugates: pharmacokinetics, biodistribution, and enhanced antitumor activity.
Cancer Res. 64: 1460-1467, 2004.
102)  Bielekova B, Richert N, Howard T, Blevins G, Markovic-Plese S, McCartin J, Frank JA, Würfel J, Ohayon J, Waldmann TA, McFarland HF, Martin R.
Humanized anti-CD25 (daclizumab) inhibits disease activity in multiple sclerosis patients failing to respond to interferon-beta.
Proc. Natl. Acad, Sci USA. 101 (23): 8705-8, 2004.
103)  Nussenblatt RB, Thompson DJ, Li Z, Chan CC, Peterson JS, Robinson RR, Shames RS, Nagarajan S, Tang MT, Mailman M, Velez G, Roy C, Levy-Clarke GA, Suhler EB, Djalilian A, Sen HN, Al-Khatib S, Ursea R, Srivastava S, Bamji A, Mellow S, Sran P, Waldmann TA, Buggage RR.
Humanized anti-interleukin-2 (IL-2) receptor alpha therapy: long-term results in uveitis patients and preliminary safety and activity data for establishing parameters for subcutaneous administration.
J Autoimmun. 21: 283-293, 2004.
104)  Klebanoff C, Finkelstein S, Surman D, Lichtman M, Gattinoni L, Theoret M, Grewal N, Spiess P, Antony P, Palmer D, Tagaya Y, Rosenber S, Waldmann T, Restifo N.
IL-15 enhances the in vivo anti-tumor activity of tumor-reactive CD8+ T cells.
Proc Natl Acad Sci USA. 101 (7): 1969-74, 2004.
105)  Oh S, Perera LP, Burke DS, Waldmann TA, Berzofsky JA.
IL-15/IL-15Ralpha-mediated avidity maturation of memory CD8+ T cells.
Proc. Natl. Acad. Sci. U.S.A. 101: 15154-9, 2004.
106)  Vámosi G, Bodnár A, Vereb G, Jenei A, Goldman CK, Langowski J, Tóth K, Mátyus L, Szöllösi J, Waldmann TA, Damjanovich S.
IL-2 and IL-15 receptor alpha-subunits are coexpressed in a supramolecular receptor cluster in lipid rafts of T cells.
Proc Natl Acad Sci U S A. 101 (30): 11082-11087, 2004.
107)  Kobayashi H, Kawamoto S, Sakai Y, Choyke P, Star R, Brechbiel M, Sato N, Tagaya Y, Morris J, Waldmann T.
Lymphatic drainage imaging of breat cancer in mice by micro-magneticresonance lymphangiography using a nano-size paramagnetic contrast agent.
J Natl Cancer Inst. 96 (9): 703-708, 2004.
108)  Kobayashi H, Kawamoto S, Brechbiel MW, Jo S, Hu X, Yang T, Diwan BA, Waldmann TA, Schnermann J, Choyke PL, Star RA.
Micro-MRI methods to detect renal cysts in mice.
Kidney Int. 65 (4): 1511-1516, 2004.
109)  Talanov VS, Yordanov AT, Garmestani K, Milenic DE, Arora HC, Plascjak PS, Eckelman WC, Waldmann TA, Brechbiel MW.
Preparation and in vivo evaluation of novel linkers for (211) At labeling of proteins.
Nucl. Med. Biol. 31(8): 1061-71, 2004.
110)  Yao Z, Zhang M, Garmestani K, Axworthy D, Mallett R, Fritzberg A, Theodore L, Plascjak P, Eckelman W, Waldmann T, Pastan I, Paik C, Brechbiel M, Carrasquillo J.
Pretargeted alpha emitting radioimmunotherapy using Bi-213 1,4,7,10-tetraazacyclododecane-N,N',N, 'N''-tetraacetic acid-biotin.
Clin Cancer Res. 10 (9): 3137-3146, 2004.
111)  Wesley J, McGee E, Garmestani K, Brechbiel M, Yordanov A, Wu C, Gansow O, Eckelman W, Bacher J, Flynn M, Goldman C, MacLin M, Schwartz U, Jackson-White T, Phillip C, Decker J, Waldmann T.
Systemic radioimmunotherapy using a monoclonal antibody, anti-Tac directed toward the alpha subunit of the IL-2 receptor armed with the alpha-emitting radionuclides (212)Bi or (211)At.
Nucl Med Biol. 31(3): 357-364, 2004.
112)  Waldmann TA.
Targeting the interleukin-15/interleukin-15 receptor system in inflammatory autoimmune diseases.
Arthritis Res Ther. 6 (4): 174-177, 2004.
113)  Nussenblatt RB, Fortin E, Schiffman R, Rizzo L, Smith J, Roy C, Velez G, Van Veldhuisen P, Sran P, Yaffe A, Bamji A, Goldman CK, Waldmann TA, Whitcup SM.
The use of monoclonal antibody therapy in the treatment of intraocular inflammatory disease (Fifth International Symposium on Uveitis).
Volume 64. p. 1460-7. [Meeting Proceeding]
114)  Waldmann TA.
A novel means of favorably tipping the balance between cytopathic and regulatory T cells.
Immunity. 19 (4): 465-466, 2003.
115)  Waldmann T.
ABCs of radioisotopes used for radioimmunotherapy: alpha- and beta-emitters.
Leuk Lymphoma. 44 Suppl 3: S107-13, 2003.
116)  Kobayashi H, Kawamoto S, Star RA, Waldmann TA, Brechbiel MW, Choyke PL.
Activated Clearance of a Biotinylated Macromolecular MRI Contrast Agent from the Blood Pool Using an Avidin Chase.
Bioconjug Chem. 14: 1044-1047, 2003.
117)  Oh S, Berzofsky JA, Burke DS, Waldmann TA, Perera LP.
Coadministration of HIV vaccine vectors with vaccinia viruses expressing IL-15 but not IL-2 induces long-lasting cellular immunity.
Proc Natl Acad Sci U S A. 100: 3392-7, 2003.
118)  Panyi G, Bagdány M, Bodnár A, Vámosi G, Szentesi G, Jenei A, Mátyus L, Varga S, Waldmann TA, Gáspar R, Damjanovich S.
Colocalization and nonrandom distribution of Kv1.3 potassium channels and CD3 molecules in the plasma membrane of human T lymphocytes.
Proc Natl Acad Sci U S A. 100: 2592-7, 2003.
119)  Kobayashi H, Kawamoto S, Choyke PL, Sato N, Knopp MV, Star RA, Waldmann TA, Tagaya Y, Brechbiel MW.
Comparison of dendrimer-based macromolecular contrast agents for dynamic micro-magnetic resonance lymphangiography.
Magn Reson Med. 50 (4): 758-766, 2003.
120)  Dubois S, Shou W, Haneline LS, Fleischer S, Waldmann TA, Müller JR.
Distinct pathways involving the FK506-binding proteins 12 and 12.6 underlie IL-2-versus IL-15-mediated proliferation of T cells.
Proc Natl Acad Sci U S A. 100 (24): 14169-14174, 2003.
121)  Vereb G, Szöllosi J, Matkó J, Nagy P, Farkas T, Vigh L, Mátyus L, Waldmann TA, Damjanovich S.
Dynamic, yet structured: The cell membrane three decades after the Singer-Nicolson model.
Proc Natl Acad Sci U S A. 100: 8053-8, 2003.
122)  Zhang Z, Zhang M, Ravetch JV, Goldman C, Waldmann TA.
Effective therapy for a murine model of adult T-cell leukemia with the humanized anti-CD2 monoclonal antibody, MEDI-507.
Blood. 102: 284-8, 2003.
123)  Zhang Z, Zhang M, Goldman CK, Ravetch JV, Waldmann TA.
Effective therapy for a murine model of adult T-cell leukemia with the humanized anti-CD52 monoclonal antibody, Campath-1H.
Cancer Res. 63 (19): 6453-6457, 2003.
124)  Waldmann TA.
IL-15 in the life and death of lymphocytes: immunotherapeutic implications.
Trends Mol Med. 9 (12): 517-521, 2003.
125)  Waldmann TA.
Immunotherapy: past, present and future.
Nat Med. 9: 269-77, 2003.
126)  Foss FM, Waldmann TA.
Interleukin-2 receptor-directed therapies for cutaneous lymphomas.
Hematol Oncol Clin North Am. 17 (6): 1449-1458, 2003.
127)  Kobayashi H, Kawamoto S, Star RA, Waldmann TA, Tagaya Y, Brechbiel MW.
Micro-magnetic resonance lymphangiography in mice using a novel dendrimer-based magnetic resonance imaging contrast agent.
Cancer Res. 63: 271-6, 2003.
128)  Zhang M, Zhang Z, Garmestani K, Schultz J, Axworthy DB, Goldman CK, Brechbiel MW, Carrasquillo JA, Waldmann TA.
Pretarget radiotherapy with an anti-CD25 antibody-streptavidin fusion protein was effective in therapy of leukemia/lymphoma xenografts.
Proc Natl Acad Sci U S A. 100: 1891-5, 2003.
129)  Waldmann TA.
The meandering 45-year odyssey of a clinical immunologist.
Annu Rev Immunol. 21: 1-27, 2003.
130)  Matkó J, Bodnár A, Vereb G, Bene L, Vámosi G, Szentesi G, Szöllösi J, Gáspár R, Horejsi V, Waldmann TA, Damjanovich S.
GPI-microdomains (membrane rafts) and signaling of the multi-chain interleukin-2 receptor in human lymphoma/leukemia T cell lines.
Eur J Biochem. 269: 1199-208, 2002.
131)  Mariner JM, Mamane Y, Hiscott J, Waldmann TA, Azimi N.
IFN regulatory factor 4 participates in the human T cell lymphotropic virus type I-mediated activation of the IL-15 receptor alpha promoter.
J Immunol. 168: 5667-74, 2002.
132)  Dubois S, Mariner J, Waldmann TA, Tagaya Y.
IL-15Ralpha recycles and presents IL-15 In trans to neighboring cells.
Immunity. 17: 537-47, 2002.
133)  Kim MK, Jeong HJ, Kao CH, Yao Z, Paik DS, Pie JE, Kobayashi H, Waldmann TA, Carrasquillo JA, Paik CH.
Improved renal clearance and tumor targeting of 99mTc-labeled anti-Tac monoclonal antibody Fab by chemical modifications.
Nucl Med Biol. 29: 139-46, 2002.
134)  Mandler R, Kobayashi H, Davis MY, Waldmann TA, Brechbiel MW.
Modifications in synthesis strategy improve the yield and efficacy of geldanamycin-herceptin immunoconjugates.
Bioconjug Chem. 13: 786-91, 2002.
135)  Eicher DM, Damjanovich S, Waldmann TA.
Oligomerization of IL-2Ralpha.
Cytokine. 17: 82-90, 2002.
136)  Zhang M, Yao Z, Garmestani K, Axworthy DB, Zhang Z, Mallett RW, Theodore LJ, Goldman CK, Brechbiel MW, Carrasquillo JA, Waldmann TA.
Pretargeting radioimmunotherapy of a murine model of adult T-cell leukemia with the alpha-emitting radionuclide, bismuth 213.
Blood. 100: 208-16, 2002.
137)  Tan C, Waldmann TA.
Proteasome inhibitor PS-341, a potential therapeutic agent for adult T-cell leukemia.
Cancer Res. 62: 1083-6, 2002.
138)  Yao Z, Zhang M, Axworthy DB, Wong KJ, Garmestani K, Park L, Park CW, Mallett RW, Theodore LJ, Yau EK, Waldmann TA, Brechbiel MW, Paik CH, Pastan I, Carrasquillo JA.
Radioimmunotherapy of A431 xenografted mice with pretargeted B3 antibody-streptavidin and (90)Y-labeled 1,4,7,10-tetraazacyclododecane-N,N',N.
Cancer Res. 62: 5755-60, 2002.
139)  Sharma S, Grandvaux N, Mamane Y, Genin P, Azimi N, Waldmann T, Hiscott J.
Regulation of IFN regulatory factor 4 expression in human T cell leukemia virus-I-transformed T cells.
J Immunol. 169: 3120-30, 2002.
140)  Waldmann T.
The contrasting roles of IL-2 and IL-15 in the life and death of lymphocytes: implications for the immunotherapy of rheumatological diseases.
Arthritis Res. 4 Suppl 3: S161-7, 2002.
141)  Waldmann TA.
The IL-2/IL-15 receptor systems: targets for immunotherapy.
J Clin Immunol. 22: 51-6, 2002.
142)  Perlin E, Engeler JE, Edson M, Karp D, McIntire KR, Waldmann TA.
The value of serial measurement of both human chorionic gonadotropin and alpha-fetoprotein for monitoring germinal cell tumors. 1976.
J Urol. 167: 934-7; discussion 938, 2002.
143)  Kennel SJ, Mirzadeh S, Eckelman WC, Waldmann TA, Garmestani K, Yordanov AT, Stabin MG, Brechbiel MW.
Vascular-targeted radioimmunotherapy with the alpha-particle emitter 211At.
Radiat Res. 157: 633-41, 2002.
144)  Gáspár R, Bagossi P, Bene L, Matkó J, Szöllosi J, Tozsér J, Fésüs L, Waldmann TA, Damjanovich S.
Clustering of class I HLA oligomers with CD8 and TCR: three-dimensional models based on fluorescence resonance energy transfer and crystallographic data.
J Immunol. 166: 5078-86, 2001.
145)  Perera LP, Goldman CK, Waldmann TA.
Comparative assessment of virulence of recombinant vaccinia viruses expressing IL-2 and IL-15 in immunodeficient mice.
Proc Natl Acad Sci U S A. 98: 5146-51, 2001.
146)  Yao Z, Garmestani K, Wong KJ, Park LS, Dadachova E, Yordanov A, Waldmann TA, Eckelman WC, Paik CH, Carrasquillo JA.
Comparative cellular catabolism and retention of astatine-, bismuth-, and lead-radiolabeled internalizing monoclonal antibody.
J Nucl Med. 42: 1538-44, 2001.
147)  Waldmann TA, Dubois S, Tagaya Y.
Contrasting roles of IL-2 and IL-15 in the life and death of lymphocytes: implications for immunotherapy.
Immunity. 14: 105-10, 2001.
148)  Alileche A, Goldman CK, Waldmann TA.
Differential effects of IL-2 and IL-15 on expression of IL-2 receptor alpha.
Biochem Biophys Res Commun. 285: 1302-8, 2001.
149)  Mariner JM, Lantz V, Waldmann TA, Azimi N.
Human T cell lymphotropic virus type I Tax activates IL-15R alpha gene expression through an NF-kappa B site.
J Immunol. 166: 2602-9, 2001.
150)  Azimi N, Nagai M, Jacobson S, Waldmann TA.
IL-15 plays a major role in the persistence of Tax-specific CD8 cells in HAM/TSP patients.
Proc Natl Acad Sci U S A. 98: 14559-64, 2001.
151)  Baldassarre G, Fedele M, Battista S, Vecchione A, Klein-Szanto AJ, Santoro M, Waldmann TA, Azimi N, Croce CM, Fusco A.
Onset of natural killer cell lymphomas in transgenic mice carrying a truncated HMGI-C gene by the chronic stimulation of the IL-2 and IL-15 pathway.
Proc Natl Acad Sci U S A. 98: 7970-5, 2001.
152)  Yordanov AT, Garmestani K, Zhang M, Zhang Z, Yao Z, Phillips KE, Herring B, Horak E, Beitzel MP, Schwarz UP, Gansow OA, Plascjak PS, Eckelman WC, Waldmann TA, Brechbiel MW.
Preparation and in vivo evaluation of linkers for 211At labeling of humanized anti-Tac.
Nucl Med Biol. 28: 845-56, 2001.
153)  White JD, Wharfe G, Stewart DM, Maher VE, Eicher D, Herring B, Derby M, Jackson-Booth PG, Marshall M, Lucy D, Jain A, Cranston B, Hanchard B, Lee CC, Top LE, Fleisher TA, Nelson DL, Waldmann TA.
The combination of zidovudine and interferon alpha-2B in the treatment of adult T-cell leukemia/lymphoma.
Leuk Lymphoma. 40: 287-94, 2001.
154)  Morris JC, Waldmann TA.
Advances in interleukin 2 receptor targeted treatment.
Ann Rheum Dis. 59 Suppl 1: i109-14, 2000.
155)  Vereb G, Matkó J, Vámosi G, Ibrahim SM, Magyar E, Varga S, Szöllosi J, Jenei A, Gáspár R, Waldmann TA, Damjanovich S.
Cholesterol-dependent clustering of IL-2Ralpha and its colocalization with HLA and CD48 on T lymphoma cells suggest their functional association with lipid rafts.
Proc Natl Acad Sci U S A. 97: 6013-8, 2000.
156)  Trovato R, Cereseto A, Takemoto S, Gessain A, Watanabe T, Waldmann T, Franchini G.
Deletion of the p16INK4A gene in ex vivo acute adult T cell lymphoma/leukemia cells and methylation of the p16INK4A promoter in HTLV type I-infected T cell lines.
AIDS Res Hum Retroviruses. 16: 709-13, 2000.
157)  Kobayashi H, Carrasquillo JA, Paik CH, Waldmann TA, Tagaya Y.
Differences of biodistribution, pharmacokinetics, and tumor targeting between interleukins 2 and 15.
Cancer Res. 60: 3577-83, 2000.
158)  Waldmann TA, Levy R, Coller BS.
Emerging Therapies: Spectrum of Applications of Monoclonal Antibody Therapy.
Hematology (Am Soc Hematol Educ Program). 394-408, 2000.
159)  Azimi N, Mariner J, Jacobson S, Waldmann TA.
How does interleukin 15 contribute to the pathogenesis of HTLV type 1-associated myelopathy/tropical spastic paraparesis?.
AIDS Res Hum Retroviruses. 16: 1717-22, 2000.
160)  Marks-Konczalik J, Dubois S, Losi JM, Sabzevari H, Yamada N, Feigenbaum L, Waldmann TA, Tagaya Y.
IL-2-induced activation-induced cell death is inhibited in IL-15 transgenic mice.
Proc Natl Acad Sci U S A. 97: 11445-50, 2000.
161)  Phillips KE, Herring B, Wilson LA, Rickford MS, Zhang M, Goldman CK, Tso JY, Waldmann TA.
IL-2Ralpha-Directed monoclonal antibodies provide effective therapy in a murine model of adult T-cell leukemia by a mechanism other than blockade of IL-2/IL-2Ralpha interaction.
Cancer Res. 60: 6977-84, 2000.
162)  Mandler R, Wu C, Sausville EA, Roettinger AJ, Newman DJ, Ho DK, King CR, Yang D, Lippman ME, Landolfi NF, Dadachova E, Brechbiel MW, Waldmann TA.
Immunoconjugates of geldanamycin and anti-HER2 monoclonal antibodies: antiproliferative activity on human breast carcinoma cell lines.
J Natl Cancer Inst. 92: 1573-81, 2000.
163)  Takemoto S, Trovato R, Cereseto A, Nicot C, Kislyakova T, Casareto L, Waldmann T, Torelli G, Franchini G.
p53 stabilization and functional impairment in the absence of genetic mutation or the alteration of the p14(ARF)-MDM2 loop in ex vivo and cultured adult T-cell leukemia/lymphoma cells.
Blood. 95: 3939-44, 2000.
164)  Kreitman RJ, Wilson WH, White JD, Stetler-Stevenson M, Jaffe ES, Giardina S, Waldmann TA, Pastan I.
Phase I trial of recombinant immunotoxin anti-Tac(Fv)-PE38 (LMB-2) in patients with hematologic malignancies.
J Clin Oncol. 18: 1622-36, 2000.
165)  Mandler R, Dadachova E, Brechbiel JK, Waldmann TA, Brechbiel MW.
Synthesis and evaluation of antiproliferative activity of a geldanamycin-Herceptin immunoconjugate.
Bioorg Med Chem Lett. 10: 1025-8, 2000.
166)  Waldmann TA.
T-cell receptors for cytokines: targets for immunotherapy of leukemia/lymphoma.
Ann Oncol. 11 Suppl 1: 101-6, 2000.
167)  Kurys G, Tagaya Y, Bamford R, Hanover JA, Waldmann TA.
The long signal peptide isoform and its alternative processing direct the intracellular trafficking of interleukin-15.
J Biol Chem. 275: 30653-9, 2000.
168)  Azimi N, Shiramizu KM, Tagaya Y, Mariner J, Waldmann TA.
Viral activation of interleukin-15 (IL-15): characterization of a virus-inducible element in the IL-15 promoter region.
J Virol. 74: 7338-48, 2000.
Click Here to View Collapsed Bibliography.

This page was last updated on 6/30/2014.